Compare GROW & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROW | MDAI |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 47.6M |
| IPO Year | N/A | N/A |
| Metric | GROW | MDAI |
|---|---|---|
| Price | $2.49 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 34.4K | ★ 286.6K |
| Earning Date | 02-11-2026 | 11-11-2025 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $8,546,000.00 | ★ $23,168,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.02 | $1.04 |
| 52 Week High | $2.78 | $3.21 |
| Indicator | GROW | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.29 | 53.39 |
| Support Level | $2.45 | $1.41 |
| Resistance Level | $2.55 | $1.77 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 64.86 | 60.68 |
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.